Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial
CONCLUSIONS: High sTK1 at BL and subsequent time-points is associated with worse prognosis in MBC patients starting 1st line endocrine therapy (ET). Patients with low sTK1 at BL have comparable outcomes on single agent or combination ET.PMID:34521624 | DOI:10.1158/1078-0432.CCR-21-1562 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - September 15, 2021 Category: Cancer & Oncology Authors: Costanza Paoletti William E Barlow Erin F Cobain Mattias Bergqvist Rita S Mehta Julie R Gralow Gabriel N Hortobagyi Kathy S Albain Lajos Pusztai Priyanka Sharma Andrew K Godwin Alastair M Thompson Daniel F Hayes James M Rae Source Type: research
Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial
CONCLUSIONS: High sTK1 at BL and subsequent time-points is associated with worse prognosis in MBC patients starting 1st line endocrine therapy (ET). Patients with low sTK1 at BL have comparable outcomes on single agent or combination ET.PMID:34521624 | DOI:10.1158/1078-0432.CCR-21-1562 (Source: Clin Med Res)
Source: Clin Med Res - September 15, 2021 Category: Research Authors: Costanza Paoletti William E Barlow Erin F Cobain Mattias Bergqvist Rita S Mehta Julie R Gralow Gabriel N Hortobagyi Kathy S Albain Lajos Pusztai Priyanka Sharma Andrew K Godwin Alastair M Thompson Daniel F Hayes James M Rae Source Type: research
Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial
CONCLUSIONS: High sTK1 at BL and subsequent time-points is associated with worse prognosis in MBC patients starting 1st line endocrine therapy (ET). Patients with low sTK1 at BL have comparable outcomes on single agent or combination ET.PMID:34521624 | DOI:10.1158/1078-0432.CCR-21-1562 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - September 15, 2021 Category: Cancer & Oncology Authors: Costanza Paoletti William E Barlow Erin F Cobain Mattias Bergqvist Rita S Mehta Julie R Gralow Gabriel N Hortobagyi Kathy S Albain Lajos Pusztai Priyanka Sharma Andrew K Godwin Alastair M Thompson Daniel F Hayes James M Rae Source Type: research
Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial
CONCLUSIONS: High sTK1 at BL and subsequent time-points is associated with worse prognosis in MBC patients starting 1st line endocrine therapy (ET). Patients with low sTK1 at BL have comparable outcomes on single agent or combination ET.PMID:34521624 | DOI:10.1158/1078-0432.CCR-21-1562 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 15, 2021 Category: Cancer & Oncology Authors: Costanza Paoletti William E Barlow Erin F Cobain Mattias Bergqvist Rita S Mehta Julie R Gralow Gabriel N Hortobagyi Kathy S Albain Lajos Pusztai Priyanka Sharma Andrew K Godwin Alastair M Thompson Daniel F Hayes James M Rae Source Type: research
Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial
CONCLUSIONS: High sTK1 at BL and subsequent time-points is associated with worse prognosis in MBC patients starting 1st line endocrine therapy (ET). Patients with low sTK1 at BL have comparable outcomes on single agent or combination ET.PMID:34521624 | DOI:10.1158/1078-0432.CCR-21-1562 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - September 15, 2021 Category: Cancer & Oncology Authors: Costanza Paoletti William E Barlow Erin F Cobain Mattias Bergqvist Rita S Mehta Julie R Gralow Gabriel N Hortobagyi Kathy S Albain Lajos Pusztai Priyanka Sharma Andrew K Godwin Alastair M Thompson Daniel F Hayes James M Rae Source Type: research
Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial
CONCLUSIONS: High sTK1 at BL and subsequent time-points is associated with worse prognosis in MBC patients starting 1st line endocrine therapy (ET). Patients with low sTK1 at BL have comparable outcomes on single agent or combination ET.PMID:34521624 | DOI:10.1158/1078-0432.CCR-21-1562 (Source: Clin Med Res)
Source: Clin Med Res - September 15, 2021 Category: Research Authors: Costanza Paoletti William E Barlow Erin F Cobain Mattias Bergqvist Rita S Mehta Julie R Gralow Gabriel N Hortobagyi Kathy S Albain Lajos Pusztai Priyanka Sharma Andrew K Godwin Alastair M Thompson Daniel F Hayes James M Rae Source Type: research
Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial
CONCLUSIONS: High sTK1 at BL and subsequent time-points is associated with worse prognosis in MBC patients starting 1st line endocrine therapy (ET). Patients with low sTK1 at BL have comparable outcomes on single agent or combination ET.PMID:34521624 | DOI:10.1158/1078-0432.CCR-21-1562 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - September 15, 2021 Category: Cancer & Oncology Authors: Costanza Paoletti William E Barlow Erin F Cobain Mattias Bergqvist Rita S Mehta Julie R Gralow Gabriel N Hortobagyi Kathy S Albain Lajos Pusztai Priyanka Sharma Andrew K Godwin Alastair M Thompson Daniel F Hayes James M Rae Source Type: research
Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial
CONCLUSIONS: High sTK1 at BL and subsequent time-points is associated with worse prognosis in MBC patients starting 1st line endocrine therapy (ET). Patients with low sTK1 at BL have comparable outcomes on single agent or combination ET.PMID:34521624 | DOI:10.1158/1078-0432.CCR-21-1562 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 15, 2021 Category: Cancer & Oncology Authors: Costanza Paoletti William E Barlow Erin F Cobain Mattias Bergqvist Rita S Mehta Julie R Gralow Gabriel N Hortobagyi Kathy S Albain Lajos Pusztai Priyanka Sharma Andrew K Godwin Alastair M Thompson Daniel F Hayes James M Rae Source Type: research
Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial
CONCLUSIONS: High sTK1 at BL and subsequent time-points is associated with worse prognosis in MBC patients starting 1st line endocrine therapy (ET). Patients with low sTK1 at BL have comparable outcomes on single agent or combination ET.PMID:34521624 | DOI:10.1158/1078-0432.CCR-21-1562 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - September 15, 2021 Category: Cancer & Oncology Authors: Costanza Paoletti William E Barlow Erin F Cobain Mattias Bergqvist Rita S Mehta Julie R Gralow Gabriel N Hortobagyi Kathy S Albain Lajos Pusztai Priyanka Sharma Andrew K Godwin Alastair M Thompson Daniel F Hayes James M Rae Source Type: research
Effects of PI3K inhibition in AI-resistant breast cancer cell lines: autophagy, apoptosis, and cell cycle progression
ConclusionThese results corroborate the lack of cross-resistance between AIs verified in the clinic, excluding autophagy as a mechanism of resistance to Ana or Let and supporting the ongoing clinical trials combining BYL-719 with AIs. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - September 8, 2021 Category: Cancer & Oncology Source Type: research
A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial
CONCLUSIONS: This is the first prospective trial of hormonal therapy in GCTs. Although there was a high CBR, the objective response rate to anastrozole was much lower than the pooled response rates of >70% to AIs reported in most retrospective series and case reports. PARAGON demonstrates the importance of prospective trials in rare cancers and the need to reconsider the role of AIs as single agents in GCTs.PMID:34412908 | DOI:10.1016/j.ygyno.2021.07.024 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - August 20, 2021 Category: Cancer & Oncology Authors: Susana N Banerjee Monica Tang Rachel L O'Connell Katrin Sjoquist Andrew R Clamp David Millan Steven Nottley Rosemary Lord Vinod Menon Mullassery Marcia Hall Charlie Gourley Tony Bonaventura Jeffrey C Goh Peter Sykes Peter T Grant Orla McNally Laura Alexan Source Type: research
A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial
CONCLUSIONS: This is the first prospective trial of hormonal therapy in GCTs. Although there was a high CBR, the objective response rate to anastrozole was much lower than the pooled response rates of >70% to AIs reported in most retrospective series and case reports. PARAGON demonstrates the importance of prospective trials in rare cancers and the need to reconsider the role of AIs as single agents in GCTs.PMID:34412908 | DOI:10.1016/j.ygyno.2021.07.024 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - August 20, 2021 Category: Cancer & Oncology Authors: Susana N Banerjee Monica Tang Rachel L O'Connell Katrin Sjoquist Andrew R Clamp David Millan Steven Nottley Rosemary Lord Vinod Menon Mullassery Marcia Hall Charlie Gourley Tony Bonaventura Jeffrey C Goh Peter Sykes Peter T Grant Orla McNally Laura Alexan Source Type: research
A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial
CONCLUSIONS: This is the first prospective trial of hormonal therapy in GCTs. Although there was a high CBR, the objective response rate to anastrozole was much lower than the pooled response rates of >70% to AIs reported in most retrospective series and case reports. PARAGON demonstrates the importance of prospective trials in rare cancers and the need to reconsider the role of AIs as single agents in GCTs.PMID:34412908 | DOI:10.1016/j.ygyno.2021.07.024 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - August 20, 2021 Category: Cancer & Oncology Authors: Susana N Banerjee Monica Tang Rachel L O'Connell Katrin Sjoquist Andrew R Clamp David Millan Steven Nottley Rosemary Lord Vinod Menon Mullassery Marcia Hall Charlie Gourley Tony Bonaventura Jeffrey C Goh Peter Sykes Peter T Grant Orla McNally Laura Alexan Source Type: research
Anastrozole as add-on therapy for cabergoline-resistant prolactin-secreting pituitary adenomas: real-life experience in male patients
ConclusionsAddition of an aromatase inhibitor (ANA) to the dopamine agonist therapy improved the control of prolactin levels and induced tumour regression. (Source: Pituitary)
Source: Pituitary - June 26, 2021 Category: Endocrinology Source Type: research
Determining the Interaction Behavior of Calf Thymus DNA with Anastrozole in the Presence of Histone H1: Spectroscopies and Cell Viability of MCF-7 Cell Line Investigations
DNA and Cell Biology, Ahead of Print. (Source: DNA and Cell Biology)
Source: DNA and Cell Biology - June 24, 2021 Category: Cytology Authors: Najmeh Zare-Feizabadi Zeinab Amiri-Tehranizadeh Atena Sharifi-Rad Parisa Mokaberi Niknaz Nosrati Fatemeh Hashemzadeh Hamid Reza Rahimi Mohammad Reza Saberi Jamshidkhan Chamani Source Type: research
